Evidence map›Paper›PMID 26965791›Full record

Trial reportMedical science monitor : international medical journal of experimental and clinical research2016

Comparison of Prednisolone, Etoricoxib, and Indomethacin in Treatment of Acute Gouty Arthritis: An Open-Label, Randomized, Controlled Trial.

Lingling Xu, Shiqun Liu, Meiping Guan, Yaoming Xue

Registry-linked trialOpen access · hybridAbstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Medical science monitor : international medical journal of experimental and clinical research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06863701 (Efficacy and Safety Study for the Combination of Etoricoxib / Betamethasone Compared to Etoricoxib for the Treatment of Patients Diagnosed With Acute Gout Arthritis), which is not on this map. Cited by 18 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 5 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06863701 phase3recruitingnot on this mapstarted 2025, after this paper: background citation

Efficacy and Safety Study for the Combination of Etoricoxib / Betamethasone Compared to Etoricoxib for the Treatment of Patients Diagnosed With Acute Gout Arthritis

TypeinterventionalSponsorLaboratorios Silanes S.A. de C.V.Ran2025 to 2027Enrolled72ConditionsGout Arthritis, Gout AttackArmsEtoricoxib + Betamethasone fixed dose, Etoricoxib fixed dose
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 5 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Non-steroidal anti-inflammatory drugs for acute gout.The Cochrane database of systematic reviews · 2021
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Effect of Naringin on Monosodium Iodoacetate-Induced Osteoarthritis Pain in Rats.Medical science monitor : international medical journal of experimental and clinical research · 2017
    Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Lingling XuDepartment of Endocrinology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China (mainland).
Shiqun LiuDepartment of Endocrinology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China (mainland).
Meiping GuanDepartment of Endocrinology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China (mainland).
Yaoming XueDepartment of Endocrinology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China (mainland).
Nanfang Hospital · CNSouthern Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAt present there are several kinds of medicine for treating acute gout arthritis (AGA). This study compared the efficacy and safety of prednisolone, etoricoxib, and indomethacin in the treatment of AGA. MATERIAL/

methodsThis was an open-label, randomized, active-comparator study in patients with AGA. Patients were randomized to 4 days of prednisolone 35 mg qd, etoricoxib 120 mg qd, or indomethacin 50 mg tid. The primary efficacy endpoint was the reduction of self-assessed pain in the index joint from baseline. Secondary endpoints included changes in physician's assessment of tenderness, erythema, swelling, and joint activity; patient assessment of response to therapy; and safety.

resultsWe analyzed 113 patients. Baseline demographics were comparable among treatment groups. Oral prednisolone, etoricoxib, and indomethacin were similarly effective in improving pain, tenderness, and joint activity over 4 days. For inflammation, oral prednisolone, etoricoxib, and indomethacin were similarly effective in reducing erythema, but prednisolone might be more effective in reducing swelling than indomethacin. The patient response to therapy was similar in the 3 groups. There were more total adverse events with indomethacin compared with the other 2 drugs.

conclusionsEfficacy was comparable among prednisolone, etoricoxib, and indomethacin for the treatment of AGA. Prednisolone might be more effective in reducing inflammation and it had a better safety profile.

Indexed as

AdultArthritis, GoutyEtoricoxibFemaleHumansIndomethacinMalePain MeasurementPrednisolonePyridinesRecurrenceSulfonesTreatment OutcomeEtoricoxibIndomethacinPrednisolonePyridinesSulfones

Identifiers

PMID26965791
PMCPMC4791088
OpenAlexW2296106507

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.